Celgene goes all-out on neurodegeneration and Alzheimer’s, triggering blockbuster deal with $150M in cash for Prothena
After quietly building up an experienced team of investigators to tackle neurodegeneration, Celgene has begun to aggressively in-license new drugs that can go after Alzheimer’s and other key diseases in the field.
Just days after Celgene fronted $50 million for a discovery deal with Vividion Therapeutics that includes neurodegeneration, the big biotech has now lined up options on three preclinical neurodegeneration drug projects partnered with Prothena. At the head of the list is a tau program, one of the key culprits that scientists believe is closely linked with the development of Alzheimer’s.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.